Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-89P represents a pseudogene related to the U4 small nuclear RNA (snRNA) family. U4 snRNAs are essential components of the spliceosome, a complex involved in pre-mRNA splicing in eukaryotic cells. However, as a pseudogene, RNU4-89P does not produce a functional product and is not involved in splicing or cellular regulatory mechanisms. Pseudogenes such as RNU4-89P are typically nonfunctional remnants of genes that have lost their ability to encode functional RNA or protein due to mutations or genomic rearrangements. There is no evidence in the current literature that RNU4-89P functions as a receptor, enzyme, transporter, or has a role as a therapeutic target, biomarker, or disease modifier[2][3][4]. RNU4-89P is a non-coding RNA pseudogene derived from the U4 small nuclear RNA family. It does not produce a functional molecule and is not considered a biological or therapeutic target. No association with disease, drug interaction, or biomarker utility has been documented. It should not be confused with the canonical U4 snRNA genes (such as RNU4-2) that play essential roles in the spliceosome and neurodevelopmental disorders[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 89, pseudogene (RNU4-89P).